Unconjugated bilirubin (UCB) injury to glial cells leads to the secretion of glutamate and elicits a typical inflammatory response. Release of pro-inflammatory cytokines may influence gliogenesis and neurogenesis, and lead to deficits in learning and memory. Glutamate metabolism dysregulation and overexpression of tumor necrosis factor-a (TNF-a) and interleukin (IL)-1b are consistent with schizophrenia neuropathology. Recently, an increased prevalence of schizophrenia was reported in individuals with Gilbert's syndrome and among those who have had elevated levels of UCB in the neonatal life. In this review, we explore the reactivity of astrocytes, neurons and microglia to UCB, the cascade of events implicated in the immunostimulant effects of UCB, as well as the role of each nerve cell type and maturation state in the neuropathology of UCB. Identification of the signaling events promoted by UCB will be relevant for developing novel therapies that might reduce the risk of brain injury and disabilities.
Introduction
In neonatal life, there is an increased production of unconjugated bilirubin (UCB), because of a shorter life span of the erythrocytes and a reduced hepatic clearance of UCB leading to its serum retention. Thus, hyperbilirubinemia is one of the most common and more important pathological conditions in the newborn. 1 It is well established that UCB is toxic to the central nervous system, causing kernicterus, even though the molecular mechanisms underlying UCB neurotoxicity are still not clarified completely. In 1904, when Schmorl autopsied 120 jaundice neonates, the majority of the brains (114) revealed diffusely yellow spots, whereas, a much more intense coloring in the basal ganglia and the medulla oblongata was observed only in about six of the neonates. 2 Two questions were raised that remain without answering: (i) Why does UCB bind more avidly to certain neurons than to others? (ii) What reason determines the different sensitivity between neurons and glia? In this regard, we have shown that astrocytes evidence an increased impairment of cell function, whereas neurons reveal higher susceptibility to cell death in the presence of high UCB levels. 3 In addition, we recently showed that UCB, at clinically relevant concentrations and short time of exposure (4 h), plays a critical role in the activation of rat-cultured astrocytes to express tumor necrosis factor-a (TNF-a) and interleukin (IL)-1b and that lipopolysaccharide accentuates these effects. 4 Exposure of rat-cultured astrocytes to UCB increases the extracellular concentration of glutamate by decreased uptake 5 and/or enhanced secretion, 4 engendering overstimulation of glutamate and N-methyl-Daspartate (NMDA) receptors (excitotoxicity). 6 It is fascinating that some papers connect neonatal hyperbilirubinemia and Gilbert's syndrome with the development of mental illness, namely schizophrenia. 7, 8 The cause of schizophrenia is unknown, but evidence suggests that this condition is associated with alterations in prefrontal connectivity involving glutamate transmission at NMDA receptors. 9 Most attractive is the suggested association between prenatal exposure to infection and the risk for schizophrenia, together with the role of cytokines in reducing dendrite development, 10 consistent with the neuropathology of schizophrenia. 11 Interestingly, we found that early exposure to UCB leads to impairment of neuronal development by reduction in the dendrite extension and ramification 12 and that this can possibly increase the risk for mental illness in later life. Thus, it is becoming apparent that the release of cytokines caused by UCB immunostimulation may trigger long-term neuropathological effects.
Influence of differentiation in nerve cell response to unconjugated bilirubin Prematurity has been considered to be a significant aggravating factor for UCB encephalopathy, as preterm newborns have an increased susceptibility to UCB toxic effects during moderate to severe neonatal jaundice. 13, 14 In addition, there is a current opinion that immaturity is associated with a greater sensitivity to neuronal sequelae by UCB and that cell viability was shown to be directly related to aging-in-culture. 15 Studies performed by us induces greater apoptosis in more immature cells when compared with older ones. In fact, we have shown that astrocytes cultured for 5 days in vitro (DIV), as well as 4 DIV neurons exposed to 86 mM UCB in the presence of 29 mM human serum albumin (HSA), reveal approximately twofold higher levels of apoptosis when compared with more differentiated astrocytes and neurons. 16 Our most recent studies using conditions that mimic a severe neonatal hyperbilirubinemia (UCB/HSA molar ratio of 1) corroborated the higher vulnerability of young nerve cells to UCB-induced apoptosis. 18, 19 Astrocytes also presented an age dependence of lactate dehydrogenase release by UCB interaction, whereas neurons showed a much lower influence of cell differentiation. Again, glutamate and TNF-a release by UCB interaction were greater in younger cells than in older cells, with astrocytes producing the highest amounts. It is noted that the release of TNF-a by neurons exposed to UCB was nearly undetectable. Interestingly, the secretion pattern of IL-1b by astrocytes reproduced that of TNF-a. 18, 19 Despite the UCB's ability to damage both neurons and astrocytes, the different response of these cellular types point to distinct pathways of neurotoxicity. This is corroborated by the fact that astrocytes are more susceptible to inhibition of glutamate uptake and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction by UCB than neurons. 3 To obtain further insight into the mechanisms underlying the increased susceptibility of less differentiated cells to UCB injurious effects, we evaluated the levels of multidrug resistance-associated protein 1 (Mrp1), an ATP-dependent export pump that transports UCB with high affinity. 20 Mrp1 levels increased linearly with cell differentiation and were higher in astrocytes than in neurons.
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Mrp1 mRNA increased similarly with maturation. These data represent the first evidence of a reduced Mrp1 expression in young neurons and astrocytes. Interestingly, studies that have examined the P-glycoprotein expression in mouse brain, another protein that participates in limiting the accumulation of substances in the central nervous system cells and in the cerebrospinal fluid, 6 verified a marked increase with postnatal maturation. 22 In addition, inhibition of Mrp1 function by MK571 in mature neurons and astrocytes was associated with an increase in UCB-induced nerve cell toxicity and immunostimulant effects, as observed by an enhanced loss of both cell viability and function, together with a higher secretion of IL-1b, TNF-a and glutamate, reinforcing the protective role of Mrp1 against UCB neurotoxic effects. 21 Collectively, these observations are a start-up point for the research, which hopefully will generate a better understanding of the proneness of premature infants to UCB encephalopathy.
Insights into astrocyte immune response to bilirubin: role of TNFR1, NF-jB and MAPK signaling cascades Cytokines have been implicated as mediators and modulators of diverse forms of neurodegeneration. 23 IL-1b, TNF-a and IL-6 are among the best characterized early-response cytokines, and recent data suggest that they may be synthesized and secreted by microglia, astrocytes and neurons. 24 In our earlier report 4 we have shown that UCB induces an immunological response in astrocytes, even after a short treatment of 4 h. For longer incubation periods, secretion of TNF-a and IL-1b reached a maximum at 12 h with a sustained elevation at 24 h after UCB addition. 25 The release of IL-6 was suppressed in the first 4 h of astrocyte incubation with UCB. However, for prolonged astroglial exposure to UCB, IL-6 showed a maximum production at 18 h. In these conditions, incubation of astrocytes with 100 mM UCB in the presence of the same amount of HSA for 24 h led to a marked increase in necrosis (B40%) and apoptosis (B16%). 26 Interestingly, TNF-a and IL-1b at the concentrations released by astrocytes exposed to UCB was shown to induce loss of cell viability. 25 Production and release of cytokines depend on inducible gene expression mediated by activation of cell signaling. Primary inflammatory stimulus may act through membrane receptors such as the TNF-a receptor 1 (TNFR1), which cause the activation of four major intracellular signaling pathways that are cascades of protein kinases, namely the three distinct mitogen-activated protein kinase (MAPK) pathways, p38, Jun-NH 2 -terminal kinase 1 and 2 (JNK1/2) and extracellular signal-regulated kinase 1 and 2 (ERK1/2), and the one leading to activation of the nuclear factor kB (NF-kB). 27 Incubation of astrocytes with 50 mM UCB and 100 mM HSA resulted in a biphasic activation of TNFR1 during the 24 h observation period. 25 The early phase was detected as early as 15 min, peaking at 1 h, and the late phase occurred at 12 h. Although the early-phase activation may result from a direct interaction of UCB with the TNFR1, we speculate that the secondary activation may be attributed to the action of IL-1b and IL-6 produced during astrocyte exposure to UCB (Figure 1 ), which are known to upregulate TNFR1. 28 Downstream from the UCB-induced expression of TNFR1, a rapid and transient activation of p38 (1-2 h), JNK1/2 (1-4 h) and ERK1/2 (2 h) was observed, with nuclear translocation of NF-kB occurring from 1 h onward with a maximal localization in the nuclei of astrocytes of B12% at 4 h, 25 which was also observed for 100 mM UCB (unpublished data). To our knowledge, only the report of Lin et al. 29 addresses this topic. The authors have shown that UCB significantly induced the p38 MAPK phosphorylation at 1 h without involving JNK activation in rat cerebellar granule neurons. However, our data indicate that exposure of neurons to 50 mM UCB only leads to a slight production of cytokines, that is 41.5 pg/ml of TNF-a, in contrast with 506.8 pg/ml produced by astrocytes in the same conditions, 18 probably accounting for the activation of the three MAPKs in our astrocyte model.
Our observations that the activation of MAPKs and NF-kB occurs between 1 and 4 h after UCB treatment and precedes the marked upregulation of cytokines reinforce the concept that UCB-induced astroglial cytokine production involves these pathways ( Figure 1) . Indeed, additional studies with selective inhibitors have recently shown that UCB elicits astroglial cytokine release and death through MAPKs and NF-kB signaling pathways with NF-kB activation occurring downstream JNK1/2 and ERK1/2 phosphorylation. 30 The dissection of the molecular mechanisms involved in UCB neurotoxicity may yield new targets on which to focus drug discovery efforts aimed at reducing brain injury and disabilities.
Role of NF-jB activation in bilirubin-induced toxicity and immunostimulation of astrocytes On the basis of our studies evidencing an activation of NF-kB by UCB, we decided to evaluate the effects of pyrrolidine dithiocarbamate (PDTC), a well-known inhibitor of NF-kB in many different cell types, 31, 32 in astroglial response to UCB. In fact, PDTC reversibly suppresses the release of the inhibitory subunit IkB from the latent cytoplasmic form of NF-kB, thus regulating its activation and subsequent DNA-binding activity. 33, 34 We used 100 mM PDTC in our inhibition studies, a concentration previously reported as being enough to block NF-kB activation. 34 PDTC revealed a 37% inhibition of the lactate dehydrogenase release produced by the exposure of astrocytes for 4 h to 100 mM UCB (Figure 2) . Interestingly, no effect was produced in UCB-induced cell death by apoptosis or by the release of glutamate, suggesting that these events do not result from NF-kB activation (unpublished data). As expected, the secretion of the pro-inflammatory cytokine TNF-a by UCB immunostimulation was inhibited by 45% in the presence of PDTC (Figure 2 ). In addition, the production of IL-1b was even more reduced (71%), whereas the suppression of IL-6 release by UCB was further enhanced by 45% in astrocytes co-incubated with PDTC. Therefore, these data indicate that UCB induces the release of cytokines and causes cell death by necrosis through a pathway that involves the activation of NF-kB.
Comparative neuronal and glial cell reactivity to bilirubin A primary brain injury stimulates microglia, astrocytes and even neurons to produce TNF-a, IL-1b and IL-6. 35 However, as microglia and astrocytes are the most active cells, neurons are relatively inert. 36 As microglia has been implicated in many pathological states, 37 we thought it would be of great interest to evaluate the reactivity of these cells to UCB and to compare its response with that of astrocytes and neurons. This will give us further insights on the relative role played by each cell type in the pathogenesis of UCB brain damage. When microglia, astrocytes and neurons were exposed to 100 mM UCB (and 100 mM HSA), it was observed that lactate dehydrogenase release did not surpass 8% over control levels, although microglia revealed an B1.8-fold increase relative to astrocytes and neurons (Figure 3 ). Microglia were also more vulnerable to UCB-induced apoptosis, revealing an increase of B2.6-and B4.5-fold when compared with astrocytes and neurons, and achieving levels of 11% over control values. 18, 38 Recent studies have indicated that some molecules released by microglia may be harmful in acute brain insults and neurodegenerative diseases. 39 Therefore, we also looked for the ability of the three cell types to release glutamate, in particular microglia. In fact, glutamate is known as a cytotoxic molecule released from activated microglia. 40, 41 The results showed that 4 h exposure of microglia to 100 mM UCB in the presence of 100 mM HSA noticeably induced the extracellular accumulation of glutamate. The release of glutamate by microglia was B4-and B8-fold over the values obtained for astrocytes and neurons, respectively (Figure 3) . 18, 38 Thus, microglia are the neural cells most susceptible to UCB-induced cell death and release of glutamate. We also have observed that cytokines are mainly Figure 1 Schematic representation of the signaling pathways involved in astrocyte reactivity to unconjugated bilirubin (UCB). UCB interaction with astrocytes causes a rapid increase of the cell surface receptor TNF-a receptor 1 (TNFR1) protein levels (arrow 1). On stimulation of TNFR1, downstream signaling cascades are induced, resulting in phosphorylation of mitogen-activated protein kinases (MAPKs), which are able to activate numerous transcription factors (TF) with consequent expression of genes important for diverse biological processes, including cell death and inflammatory responses, through the secretion of cytokines tumor necrosis factor-a (TNF-a), interleukin (IL)-1b and IL-6. TNFR1 signaling may also involve nuclear factor kB (NF-kB) activation and consequent translocation into the nucleus, where it promotes the upregulation of cytokines. In addition, UCB may rapidly diffuse through the cell membrane, directly inducing the activation of MAPKs (arrow 2) and NF-kB (arrow 3). The overall signal transduction pathway further occurs by the engagement of TNF-a with its cognate receptor TNFR1 (arrow 4). JNK1/2, Jun-NH 2 -terminal kinase 1 and 2; ERK1/2, extracellular signal-regulated kinase 1 and 2.
produced by activated microglia. Comparative secretion of TNF-a by the three nerve cell types indicate that astrocytes produce B4-fold more than neurons and microglia B24-fold more than astrocytes ( Figure 3) . Release of IL-1b was not detectable in neurons and again microglia was the main producer of this pro-inflammatory cytokine (85 pg/10 5 cells in microglia vs 11 pg/10 5 cells in astrocytes). Interestingly, the secretion of IL-6 that was suppressed by UCB in astrocytes was slightly increased in neurons (7 pg/10 5 cells) and markedly enhanced in microglia (203 pg/10 5 cells). 18, 38 Collectively, our data support the conclusion that microglia are the neural cells most responsive to UCB-induced release of cytokines.
Identification of MAPK pathways activated by bilirubin in microglia As described above, UCB was shown to trigger microglial activation in vitro. The production of pro-inflammatory cytokines is an example of the several potentially cytotoxic molecules that are produced by activated microglia. 37 To test whether MAPK pathways are involved in microglial release of the cytotoxic cytokines, we treated microglial cultures with UCB and measured activation of the three major MAPK pathways, p38, ERK1/2 and JNK1/2, by western blot analysis. Stimulation of microglia with UCB led to a rapid and transient activation of JNK1/2, ERK1/2 and p38, with the peak levels of each phosphorylated-MAPK occurring at 15-60 min after UCB addition, followed by a decline, and reaching the lowest level at 2 h (unpublished data). Although the activation profile of each MAPK in microglia differ somewhat in terms of the temporal pattern from that obtained in astrocytes, our results show that all the three MAPK pathways are activated in microglia and in astrocytes in response to UCB. Activation of the three different MAPKs in microglia was also found to occur by other stimuli, such as lipopolysaccharide, S100B and b-amyloid. 42 The relative significance of each of the MAPK pathways to UCB-induced cytokine production deserves further clarification. Control UCB/HSA 1.0 Figure 3 Microglia is the most reactive neural cell to unconjugated bilirubin (UCB). Rat cortical astrocytes, neurons and microglia were cultured for 10, 8 and 20 days in vitro, respectively, and incubated with either no addition (control) or 100 mM purified UCB, in the presence of 100 mM human serum albumin (HSA), at pH 7.4, for 4 h, at 37 1C. Cell death by necrosis was estimated by the release of intracellular lactate dehydrogenase (LDH). Release of glutamate and tumor necrosis factor-a (TNF-a) to the incubation media was assessed by an enzymatic assay and enzyme-linked immunosorbent assay (ELISA), respectively. Values are means ± s.e.m. of at least three independent experiments. *P<0.05 and **P<0.01 vs respective control and ww P<0.01 vs neurons and astrocytes.
Conclusions
Recent years have seen remarkable advances in our understanding of how UCB induces neurotoxicity. Many challenges remain however. In this paper, the increased reactivity of undifferentiated astrocytes and neurons to UCB was highlighted as an important issue in the increased susceptibility of premature babies to kernicterus and other subtle neurologic abnormalities associated with hyperbilirubinemia. UCB effects also depend on neural cell type. In fact, on UCB interaction, microglia showed the highest potential to release glutamate and cytokines, closely followed by astrocytes, whereas neurons were relatively inert. Stimulation of astrocytes and microglia with UCB led to a rapid and transient activation of p38, ERK1/2 and JNK1/2, with the release of cytokines occurring at later times. NF-kB pathway was shown to mediate UCB-induced release of lactate dehydrogenase and immunostimulation of astrocytes. The use of selective MAPK inhibitors showed that MAPKs (JNK1/2 and ERK1/2) are involved in NF-kB activation by UCB and that all kinases are implicated in the UCB-induced secretion and/or expression of cytokines, indicating a potential area for future therapeutic intervention.
